상세 정보

underline
Metadata Downloads : dc(xml) or Excel
Cited 0 time in scopus ci

Title 

Effect of molecular imaging on validation of developed anti-hVEGFR2 therapeutic antibody

Authors 

S J CheongC M LeeD JangE M KimM H JeongT B UhmWeon Sup LeeH J JeongD W KimS T LimM H Sohn

Publisher 

Mary Ann Liebert

Issue Date 

2011

Citation 

Cancer Biotherapy and Radiopharmaceuticals, vol. 26, no. 6, pp. 745-751

Keywords 

anti-hVEGFR2 antibodygene transfectionhuman sodium iodide symporter (hNIS)molecular imagingreporter gene

Abstract 

Vascular endothelial growth factor receptor type 2 (VEGFR2)-targeted tumor treatment is an antiangiogenic therapeutic strategy. The human sodium iodide symporter (hNIS) gene is a useful reporter gene for tumor imaging and radiotherapy. In this study, we investigated the evaluation of therapeutic efficacy in hNIS gene-transfected tumor xenografts using a gamma imaging system after treatment with an anti-VEGFR2 antibody. Human breast cancer MDA-MB-231 cells transfected with the hNIS gene were injected subcutaneously into the right flanks of BALB/c nude mice. Therapy was initiated when the tumor volume reached approximately 130-180 mm 3. The animals were intravenously injected with 50, 100, or 150 μg of antibody every 3 days for 16 days. Gamma imaging was performed 1 and 2 weeks after the first injection to monitor the effects of tumor therapy. Mice were sacrificed 2 weeks after the first injection of antibody and the tumors were removed for CD31 staining and reverse transcription-polymerase chain reaction (RT-PCR) assay. All groups of mice that were treated with anti-hVEGFR2 antibody showed markedly reduced tumor growth compared to control mice. In vivo gamma imaging results showed that, at 1 week after the first injection of the anti-hVEGFR2 antibody, 125I uptake of a tumor treated with 150 μg of antibody was 24.5% lower than that in the controls. At 2 weeks, 125I uptake in the tumor treated with 150 μg of antibody was as low as 44.3% of that in the controls. CD31 staining and RT-PCR assays showed that blood vessel formation and expression of the hNIS gene were reduced with increased treatment doses. This study demonstrated the feasibility of molecular imaging and the therapeutic efficacy of developing therapeutic antibody anti-hVEGFR2 using a gamma imaging system in hNIS gene-transfected tumor xenograft mice.

ISSN 

1084-9785

Link 

http://dx.doi.org/10.1089/cbr.2011.0996

Appears in Collections

1. Journal Articles > Journal Articles

Registered Date

2019-05-02


There are no files associated with this item.
qrcode

FusionCharts.
DSpace Software Coptright(c) 2010 MIT and Hewleft-Packard  /  KRIBB-REPOSITORY ( Email:jakim@kribb.re.kr)